Amgen 4Q Revenues: $5.0 billion (+13%) 4Q Earnings: $1.0 billion (+30%) FY Revenues: $18.7 billion (+8%) FY Earnings: $5.1 billion (+17%) Comments: Total product sales increased 11% in the quarter to $4.8 billion. Combined Neulastaand NEUPOGEN sales were up 8% in the quarter to $1.4 billion. Enbrel sales were up 3% to $1.2 billion. Aranesp sales decreased 4% to $470 million in the quarter, due to lower demand. EPOGEN sales increased 10% to $525 million. Sensipar/Mimparasales increased 20% t...